On Mar. 16, 2021, Moderna announced that the first participants had been dosed in the Phase 2/3 study, called the KidCOVE study, of mRNA-1273, the Companyﾒs vaccine candidate against COVID-19, in children ages 6 months to less than 12 years.

The study is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases and the Biomedical Advanced Research and Development Authority.